Wednesday, August 6, 2014

Johnson & Johnson (JNJ) Dividend Stock Analysis 2014

Johnson & Johnson (JNJ), together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. This dividend king has paid dividends since 1944 and has managed to increase them for 52 years in a row.

The company’s latest dividend increase was announced in April 2014 when the Board of Directors approved a 6.10% increase in the quarterly dividend to 70 cents /share. The company’s peer group includes Novartis (NVS), Pfizer (PFE) and Covidien (COV).

Over the past decade this dividend growth stock has delivered an annualized total return of 12.10% to its shareholders.

Currently, the stock is attractively valued at 17.80 times forward earnings and a current yield of 2.70%. I last purchased shares of the stock in 2013, and the only reason I am hesitating to add more is because the company is one of the five highest weighted in my portfolio.

Check the full analysis at Seeking Alpha

Full Disclosure: Long JNJ

Relevant Articles:

Multi-Generational Dividend investing
Dividend Investors Will Make Money Even if the Stock Market Closed for Ten Years
Can everyone achieve financial independence with Dividend Paying Stocks?
Dividend Growth Stocks are Compounding Machines
Two Dividend Kings Extending Their Dividend Growth Streaks


  1. Good info DGI. I will keep watching and might buy at $90 or less.

  2. DGI,

    JNJ is one stock I need to add to my portfolio. The entry yield is decent and the long term dividend growth is fantastic. It seems like JNJ, PG, and Exxon are always difficult to find good entry points in.


  3. More than happy to DRIP this dividend stud.


Questions or comments? You can reach out to me at my website address name at gmail dot com.

Popular Posts